Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial

What Was Tested

This randomized controlled trial paper looks at Liraglutide in the context of fatty liver & elevated liver enzymes.

To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease.

Who Took Part

The abstract describes 85 patients taking part.

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

The timeline in the abstract includes 24 weeks.

Body composition was measured using dual-energy X-ray absorptiometry.

What Was Measured

PubMed files the paper under topics including Biomarkers, Blood Glucose, Body Composition, Diabetes Mellitus, Type 2, Gliclazide, Glycated Hemoglobin and Hypoglycemic Agents.

Author keywords: Antidiabetic agents and Type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized study of Liraglutide in 85 patients in people with fatty liver & elevated liver enzymes over 24 weeks.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Journal of diabetes investigation), a journal based in Japan.

More context: the Liraglutide compound page, Fatty liver & elevated liver enzymes research.